Literature DB >> 20106929

Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4.

James E Robinson1, Kelly Franco, Debra Holton Elliott, Mary Jane Maher, Ashley Reyna, David C Montefiori, Susan Zolla-Pazner, Miroslaw K Gorny, Zane Kraft, Leonidas Stamatatos.   

Abstract

Monoclonal antibodies (MAbs) that neutralize human immunodeficiency virus type 1 (HIV-1) have been isolated from HIV-1-infected individuals or animals immunized with recombinant HIV-1 envelope (Env) glycoprotein constructs. The epitopes of these neutralizing antibodies (NAbs) were shown to be located on either the variable or conserved regions of the HIV-1 Env and to be linear or conformational. However, one neutralizing MAb, 2909, which was isolated from an HIV-1-infected subject, recognizes a more complex, quaternary epitope that is present on the virion-associated functional trimeric Env spike of the SF162 HIV-1 isolate. Here, we discuss the isolation of 11 anti-HIV NAbs that were isolated from three rhesus macaques infected with the simian/human immunodeficiency virus SHIV(SF162P4) and that also recognize quaternary epitopes. A detailed epitope mapping analysis of three of these rhesus antibodies revealed that their epitopes overlap that of the human MAb 2909. Despite this overall similarity in binding, however, differences in specific amino acid and glycosylation pattern requirements for MAb 2909 and the rhesus MAbs were identified. These results highlight similarities in the B-cell responses of humans and macaques to structurally complex neutralization epitopes on related viruses, HIV-1 and SHIV.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20106929      PMCID: PMC2838135          DOI: 10.1128/JVI.02617-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies.

Authors:  Shi-Hua Xiang; Najah Doka; Rabeéa K Choudhary; Joseph Sodroski; James E Robinson
Journal:  AIDS Res Hum Retroviruses       Date:  2002-11-01       Impact factor: 2.205

2.  Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.

Authors:  M K Gorny; J Y Xu; S Karwowska; A Buchbinder; S Zolla-Pazner
Journal:  J Immunol       Date:  1993-01-15       Impact factor: 5.422

3.  A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

Authors:  J M Binley; R W Sanders; B Clas; N Schuelke; A Master; Y Guo; F Kajumo; D J Anselma; P J Maddon; W C Olson; J P Moore
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.

Authors:  P N Nyambi; H A Mbah; S Burda; C Williams; M K Gorny; A Nádas; S Zolla-Pazner
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.

Authors:  A Ly; L Stamatatos
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate.

Authors:  M W Cho; M K Lee; C H Chen; T Matthews; M A Martin
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

7.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

8.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

9.  The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.

Authors:  Abraham Pinter; William J Honnen; Yuxian He; Miroslaw K Gorny; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.

Authors:  Avishek Nandi; Christine L Lavine; Pengcheng Wang; Inna Lipchina; Paul A Goepfert; George M Shaw; Georgia D Tomaras; David C Montefiori; Barton F Haynes; Philippa Easterbrook; James E Robinson; Joseph G Sodroski; Xinzhen Yang
Journal:  Virology       Date:  2009-11-17       Impact factor: 3.616

View more
  35 in total

Review 1.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

2.  Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1.

Authors:  Anita Changela; Xueling Wu; Yongping Yang; Baoshan Zhang; Jiang Zhu; Glenn A Nardone; Sijy O'Dell; Marie Pancera; Miroslaw K Gorny; Sanjay Phogat; James E Robinson; Leonidas Stamatatos; Susan Zolla-Pazner; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

3.  The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.

Authors:  Rebecca M Lynch; Rong Rong; Saikat Boliar; Anurag Sethi; Bing Li; Joseph Mulenga; Susan Allen; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

4.  Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Authors:  Penny L Moore; Elin S Gray; Daniel Sheward; Maphuti Madiga; Nthabeleng Ranchobe; Zhong Lai; William J Honnen; Molati Nonyane; Nancy Tumba; Tandile Hermanus; Sengeziwe Sibeko; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Abraham Pinter; Lynn Morris
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

5.  Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities.

Authors:  Chavdar Krachmarov; Zhong Lai; William J Honnen; Aidy Salomon; Miroslaw K Gorny; Susan Zolla-Pazner; James Robinson; Abraham Pinter
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

6.  Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation.

Authors:  Tongqing Zhou; Nicole A Doria-Rose; Cheng Cheng; Guillaume B E Stewart-Jones; Gwo-Yu Chuang; Michael Chambers; Aliaksandr Druz; Hui Geng; Krisha McKee; Young Do Kwon; Sijy O'Dell; Mallika Sastry; Stephen D Schmidt; Kai Xu; Lei Chen; Rita E Chen; Mark K Louder; Marie Pancera; Timothy G Wanninger; Baoshan Zhang; Anqi Zheng; S Katie Farney; Kathryn E Foulds; Ivelin S Georgiev; M Gordon Joyce; Thomas Lemmin; Sandeep Narpala; Reda Rawi; Cinque Soto; John-Paul Todd; Chen-Hsiang Shen; Yaroslav Tsybovsky; Yongping Yang; Peng Zhao; Barton F Haynes; Leonidas Stamatatos; Michael Tiemeyer; Lance Wells; Diana G Scorpio; Lawrence Shapiro; Adrian B McDermott; John R Mascola; Peter D Kwong
Journal:  Cell Rep       Date:  2017-04-25       Impact factor: 9.423

7.  epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals.

Authors:  Haili Tang; James E Robinson; S Gnanakaran; Ming Li; Eric S Rosenberg; Lautaro G Perez; Barton F Haynes; Hua-Xin Liao; Celia C Labranche; Bette T Korber; David C Montefiori
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

8.  Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120.

Authors:  Brett Spurrier; Jared M Sampson; Maxim Totrov; Huiguang Li; Timothy O'Neal; Constance Williams; James Robinson; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  Structure       Date:  2011-05-11       Impact factor: 5.006

9.  The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Authors:  Nicos Karasavvas; Erik Billings; Mangala Rao; Constance Williams; Susan Zolla-Pazner; Robert T Bailer; Richard A Koup; Sirinan Madnote; Duangnapa Arworn; Xiaoying Shen; Georgia D Tomaras; Jeffrey R Currier; Mike Jiang; Craig Magaret; Charla Andrews; Raphael Gottardo; Peter Gilbert; Timothy J Cardozo; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Robert Paris; Kelli Greene; Hongmei Gao; Sanjay Gurunathan; Jim Tartaglia; Faruk Sinangil; Bette T Korber; David C Montefiori; John R Mascola; Merlin L Robb; Barton F Haynes; Viseth Ngauy; Nelson L Michael; Jerome H Kim; Mark S de Souza
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205

10.  A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.

Authors:  Laura M Walker; Melissa D Simek; Frances Priddy; Johannes S Gach; Denise Wagner; Michael B Zwick; Sanjay K Phogat; Pascal Poignard; Dennis R Burton
Journal:  PLoS Pathog       Date:  2010-08-05       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.